| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:PLX 647 dihydrochloride
CAS:1779796-38-1
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
Nantong Hi-Future Biotechnology Co., Ltd
|
| Tel: |
18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:PLX 647 dihydrochloride
CAS:1779796-38-1
Purity:98% HPLC Package:100mg，500mg，1g，5g，10g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PLX647 dihydrochloride
CAS:1779796-38-1
Package:25mg/RMB 10600
|
|
| | 5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-2-pyridinamine dihydrochloride Basic information |
| | 5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-2-pyridinamine dihydrochloride Chemical Properties |
| | 5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-2-pyridinamine dihydrochloride Usage And Synthesis |
| Uses | PLX647 dihydrochloride is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC50s=91 and 130 nM, respectively)[1]. | | in vivo | PLX647 dihydrochloride (40 mg/kg; p.o.; twice daily for 7 days) reduces macrophage accumulation in UUO kidney and blood monocytes[1].
PLX647 dihydrochloride (40 mg/kg; p.o.; male Swiss Webster mice) reduces LPS-induced TNF-α and IL-6 release[1].
PLX647 dihydrochloride (20-80 mg/kg; p.o.; daily or twice daily from 27-41 days) shows effects on collagen-induced arthritis[1].
PLX647 dihydrochloride (30 mg/kg) results in significant inhibition of TRAP5b immunostaining and bone osteolysis. PLX647 dihydrochloride (30 mg/kg BID) is able to prevent bone damage by the tumor cells[1]. | Animal Model: | Male C57BL/6 mice (mouse unilateral ureter obstruction model)[1] | | Dosage: | 40 mg/kg | | Administration: | P.o.; twice daily for 7 days | | Result: | Resulted in reduction in the levels of F4/80+ macrophages by 77%. |
| Animal Model: | 7-9 wk old Male DBA/1J mice (Mouse collagen-induced arthritis model)[1] | | Dosage: | 20 mg/kg, 80 mg/kg | | Administration: | P.o.; daily (20 mg/kg) from 27-41 days, twice daily (80 mg/kg) from 27-41 days | | Result: | 20 mg/kg PLX647 had no initial effect on the development of severe arthritis. However, starting on day 33, no further development of disease severity was recorded, and a 30% inhibition of the macroscopic signs of arthritis was evident in clinical score on day 41. Mice treated with 80 mg/kg BID PLX647 initially shows delayed development of severe arthritic signs. Starting on day 33, the signs of arthritis began to decrease in this treatment group, reaching a maximum reversal of 76% on day 41.
|
| | References | [1] Zhang C, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94. DOI:10.1073/pnas.1219457110 |
| | 5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-2-pyridinamine dihydrochloride Preparation Products And Raw materials |
|